Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia

June 11, 2024 updated by: Yuanjiao Yan, Fujian Provincial Hospital
Dementia is a chronic, progressive neurodegenerative disease characterized by acquired cognitive impairment as its core manifestation. The most common type of dementia is Alzheimer's Disease (AD), also known as "Senile Dementia," accounting for 60-80% of all dementia cases. Currently, there are approximately 10 million AD patients in China, with the number showing an increasing trend year by year, imposing a heavy economic and caregiving burden on families and society. Studies have shown that AD has a clinically silent period of 15 to 20 years (SCD\MCI), where the risk of developing dementia is ten times higher than that of healthy elderly individuals. Nearly 50% of MCI patients progress to dementia within 5 years, and about 14.1% of SCD patients develop dementia within the same timeframe. Early detection, diagnosis, and intervention are currently the most effective strategies for preventing and treating AD. Therefore, this study aims to verify the intervention effect of integrated cognitive intervention in high-risk populations for senile dementia (SCD, MCI) based on the cognitive rehabilitation model through randomized controlled trials, and to analyze attrition rates, participation rates, etc., which have good research and application value.

Study Overview

Status

Recruiting

Detailed Description

Based on the cognitive rehabilitation model, this study aims to develop a digital multimodal cognitive intervention program, and conduct feasibility studies and randomized controlled trials. The intervention includes health knowledge education, exercise intervention, art intervention, and cognitive training, etc. The feasibility, effectiveness, and safety of this intervention approach will be evaluated.

Study Type

Interventional

Enrollment (Estimated)

172

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: lian fayang, MD
  • Phone Number: 86 0591-87557768
  • Email: fjslkyk@163.com

Study Contact Backup

Study Locations

    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Recruiting
        • Fujian Provincial Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • MCI (refer to Peterson's diagnostic criteria) or SCD (refer to the diagnostic framework proposed by Jak bondi and Jessen et al.);
  • Able to communicate normally in Mandarin;
  • Certain level of comprehension and judgment abilities, aware of the purpose of the survey and consents to participate.

Exclusion Criteria:

  • Patients with dementia exhibiting abnormal mental behavior;
  • Individuals with severe hearing or speech impairments;
  • Those with serious physical illnesses who are unable to cooperate and complete the survey.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Participants in the intervention group received the digtal multi-domain cognitive intervention. The digital multi-domain cognitive intervention system is used to carry out various intervention activities. The activities include learning about health knowledge once a week; home-based exercise three times per week, for 30 minutes each time; art therapy once a week, for 90 minutes at a time; and cognitive training, which includes memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.
  • Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.

    • Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.

      • Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.

        • Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly.
Other: Control group
Participant in the control group reveived the health education , once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly
  • Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.

    • Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.

      • Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.

        • Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global cognitive function
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Montreal Cognitive Assessment will be used to assess the global cognitive function.The scale has a total score of 30 points, encompassing eight assessment sections: visual-spatial and executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. It involves multiple cognitive domains. A higher score indicates better cognitive functioning.
Baseline (pre-intervention), six-month follow-up (post-intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Memory
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Auditory Verbal Learning Test will be used to assess the memory. This includes immediate memory, short-term memory, long-term memory, and recognition memory. A higher score indicates better memory performance.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Verbal fluency
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Verbal Fluency Test will be used to assess the verbal fluency. A higher score indicates better verbal language performance.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Naming difficulty
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Boston Naming Test will be used to assess the naming difficulty. The total scores range from 0 to 30, a higher score indicates better language functioning.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Executive function
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Shape Trail Test will be used to assess the execuite function. The shorter the usage time indicates better executive functioning.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Visuospatial skills
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Chinese version of Rey-Osterrieth Complex Figure Test will be used to assess the visuospatial skills. A higher score indicates better visual-spatial structural abilities.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Health-Promoting Lifestyle
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Chinese version of Health-Promoting Lifestyle Profile-II will be used to assess the health lifestyle . The total score range from 40 to 160. A higher score indicates better health lifestyle.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Abilities for health practices
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Chinese version of self-rated abilities for health practices scale will be used to assess the ability of health practice. The total score range from 0 to 112. A higher score indicates higher self-efficacy in healthy behaviors.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Lonliness
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The University of California at Los Angels Loneliness scale will be used to assess the loneliness. A higher score indicates more lonliness.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Social network
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Lubben Social Network Scale will be used to assess the social network. The lower score indicates lower risk of social isolation.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Depression
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Geriatric Depression Scale will be used to assess the depression. The Cronbach coefficient of this scale is 0.93.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Self-efficacy
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Chinese version of Self-efficacy Scale will be used to assess the self-efficacy. The total score range from 10 to 40.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Self-esteem
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Self-esteem Scale will be used to assess the self-esteem. A higher score indicates higher level of Self-esteem.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Sleep quality
Time Frame: Baseline (pre-intervention), six-month follow-up (post-intervention)
The Athens Insomnia Scale will be used to assess the sleep quality.The Cronbach coefficient of this scale is 0.89, highest score is 24.
Baseline (pre-intervention), six-month follow-up (post-intervention)
Subjective cognitive function
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Subjective Cognitive Decline Questionnaire 9 will be used to assess the subjective cognitive function. The Cronbach coefficient of this scale is 0.88, highest score is 9.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Quality of life of Alzheimer's disease
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Quality of life-Alzheimer's disease scale will be used the quality of life. A higher score indicates better quality of life. The highest score is 39 points.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
Anxiety
Time Frame: Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)
The Self-rating Anxiety Scale will be used to assess the anxiety. The subjects will fill in the form based on their own situation in the past week.
Baseline (pre-intervention), three-month follow-up(during the intervention), six-month follow-up (post-intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Yuanjiao Yan, PhD, Shengli clinical medical college of Fujian Medical university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 4, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

May 29, 2024

First Submitted That Met QC Criteria

June 4, 2024

First Posted (Actual)

June 5, 2024

Study Record Updates

Last Update Posted (Actual)

June 12, 2024

Last Update Submitted That Met QC Criteria

June 11, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Research data and research-related materials will be available in a repository or online. After completion of the study, relevant data will be provided in the form of a universal resource locator or digital object identifier.

IPD Sharing Time Frame

After completion of the study, relevant data will be provided in the form of a universal resource locator or digital object identifier.

IPD Sharing Access Criteria

Researchers whose proposed use of the data has been approved

IPD Sharing Supporting Information Type

  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Dysfunction

Clinical Trials on Multi-domain Cognitive Intervention

Subscribe